Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 November 2021 | Story Lunga Luthuli | Photo Andre Ferreira
UFS Council Chambe
The refurbished Council Chambers of the University of the Free State was recognised with a South African Institute of Architects Free State Regional Award for Architectural Projects.

Winning three South African Institute of Architects (SAIA) Free State Regional Awards is the embodiment of the University of the Free State’s (UFS) commitment to continually improve infrastructure and create accessible spaces. 

Two of the UFS projects – the Council Chambers and the Modular Lecture Space and Assessment Centre – emerged victorious in the category for Architectural Projects, while Prof Jonathan Noble, Head of the Department of Architecture, won an award in Category B – Work of Social Importance – for his book, The Architecture of Peter Rich: Conversations with Africa. 
SAIA members were invited to submit Free State- and Northern Cape-based projects, completed between 1 January 2019 and 31 March 2021, for regional adjudication by a panel of judges consisting of professional architects Jeremie Malan, Diaan van der Westhuizen, and Velka Laubscher.

Each participating project were visited on 29 and 30 September 2021; the panel  was ‘delighted with the quality of workmanship’. 

Velka Laubscher, President of the South African Institute of Architects in the Free State, says: “The Regional Awards Programme is held biennially, and each visited project was adjudicated and awarded based on merit, looking at design, aesthetics, commodity, and orientation. 

“The panel of adjudicators also follows specific guidelines to ensure that the process adheres to SAIA’s standards,” says Laubscher.

Nico Janse van Rensburg, Senior Director: University Estates at the UFS, says, “It is a great honour to receive these accolades, as our buildings are constructed on carefully controlled budgets, but still manage to exhibit a refinement in terms of architectural aesthetics. The recognition also reflects how the institution’s infrastructure performs compared to university buildings in general.”

The Department of Higher Education and Training recently recommended the UFS to other universities in the country to learn from the institution how to undertake infrastructural development while adhering to budget constraints. 

The main criteria for projects to receive SAIA recognition not only involve compliance with a functional programme, but should also deal intelligently with contextual informants, creating spaces that offer opportunities for meaningful interaction, and the use of materials and measures that are sympathetic to the environment in general, as well as to our local climate conditions.

“We welcome the recognition by the department, as it gives us an opportunity to also interact and learn from other universities, since there is always room for improvement. The university community can rest assured that the allocated budget is spent to reflect the institution’s objectives and to get value for money,” says Janse van Rensburg.

Anton Roodt, architect and urban planner from GXY Architects and Roodt Architects joint consultants, says: “The value for the University of the Free State lies in the fact that the university is seen, both by its internal and external stakeholders, as an institution that values the contribution that good architecture can add to academic programmes and projecting the image of the university as an enlightened institution.” 

Projects awarded with a ‘Regional Award for Architecture 2021’ will now be submitted for national adjudication to become eligible for a SAIA Award of Merit 2022 and a SAIA Award for Excellence 2022.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept